A 2D Nanoradiosensitizer Enhances Radiotherapy and Delivers STING Agonists to Potentiate Cancer Immunotherapy
Source abstract
Abstract
Abstract Despite potent preclinical antitumor activity, activation of stimulator of interferon genes (STING) has shown modest therapeutic effects in clinical studies. Many STING agonists, including 2′,3′‐cyclic guanosine monophosphate–adenosine monophosphate (cGAMP), show poor pharmacokinetic properties for sustaining STING activation in tumors and achieving optimal antitumor efficacy. Improved delivery of STING agonists and their effective combination with other treatments are needed to enhance their therapeutic effects. Herein, a 2D nanoplatform, cGAMP/MOL, is reported via conjugating cGAMP to a nanoscale metal–organic layer (MOL) for simultaneous STING activation and radiosensitization. The MOL not only exhibits strong radiosensitization effects for enhanced cancer killing and induction of immunogenic cell death, but also retains cGAMP in tumors for sustained STING activation. Compared to free cGAMP, cGAMP/MOL elicits stronger STING activation and regresses local tumors upon X‐ray irradiation. Further combination with an immune checkpoint inhibitor bridges innate and adaptive immune systems by activating the tumor microenvironment to elicit systemic antitumor responses.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: interferon and immune responses · Nanoplatforms for cancer theranostics · Peptidase Inhibition and Analysis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Chemistry The University of Chicago Chicago IL 60637 USA
Department of Radiation and Cellular Oncology and the Ludwig Center for Metastasis Research The University of Chicago Chicago IL 60637 USA
Department of Pathology & University of Chicago Comprehensive Cancer Center The University of Chicago Chicago IL 60637 USA
Funding
National Cancer Institute
References (57)
Show source-provided references
1. 10.1038/nrendo.2016.20510.1038/nrendo.2016.205 ↗
2. 10.1038/s41591-019-0564-610.1038/s41591-019-0564-6 ↗
3. 10.1038/cr.2016.14910.1038/cr.2016.149 ↗
4. 10.1038/s41586-019-1593-510.1038/s41586-019-1593-5 ↗
5. 10.1186/s12943-019-1087-y10.1186/s12943-019-1087-y ↗
6. 10.1126/science.123245810.1126/science.1232458 ↗
7. 10.1126/science.122996310.1126/science.1229963 ↗
8. 10.3390/jcm910332310.3390/jcm9103323 ↗
9. 10.1038/s41467-017-01566-510.1038/s41467-017-01566-5 ↗
10. 10.1093/annonc/mdy424.01510.1093/annonc/mdy424.015 ↗
11. 10.1200/JCO.2019.37.15_suppl.250710.1200/JCO.2019.37.15_suppl.2507 ↗
12. 10.1038/s41578-019-0108-110.1038/s41578-019-0108-1 ↗
13. 10.1038/s41551-020-00675-910.1038/s41551-020-00675-9 ↗
14. 10.1038/nrc300710.1038/nrc3007 ↗
15. 10.1038/nrclinonc.2016.21110.1038/nrclinonc.2016.211 ↗
16. 10.1186/s40425-016-0156-710.1186/s40425-016-0156-7 ↗
17. 10.1001/jamaoncol.2019.147810.1001/jamaoncol.2019.1478 ↗
18. 10.1200/JCO.2018.36.15_suppl.101210.1200/JCO.2018.36.15_suppl.1012 ↗
19. 10.1200/JCO.2016.34.15_suppl.TPS207910.1200/JCO.2016.34.15_suppl.TPS2079 ↗
20. Manukian G. · Front. Oncol. · 2019 · 22 · 9
21. 10.3389/fonc.2020.60877210.3389/fonc.2020.608772 ↗
22. 10.1038/s41551-018-0203-410.1038/s41551-018-0203-4 ↗
23. 10.1021/jacs.9b1259310.1021/jacs.9b12593 ↗
24. 10.1038/nmeth.385310.1038/nmeth.3853 ↗
25. 10.1038/nprot.2006.33910.1038/nprot.2006.339 ↗
26. 10.1038/nature0766810.1038/nature07668 ↗
27. 10.1038/s41467-018-04703-w10.1038/s41467-018-04703-w ↗
28. 10.1038/nrc338010.1038/nrc3380 ↗
29. 10.1007/s00018005006710.1007/s000180050067 ↗
30. 10.1038/nm152310.1038/nm1523 ↗
31. 10.1021/accountsmr.1c0016110.1021/accountsmr.1c00161 ↗
32. 10.1002/jcp.104110020710.1002/jcp.1041100207 ↗
33. Baker S. B. · Crit. Care Resusc. · 2002 · 4 · 301
34. 10.1007/s00467-012-2175-z10.1007/s00467-012-2175-z ↗
35. 10.1038/s41467-018-06922-710.1038/s41467-018-06922-7 ↗
36. 10.1038/s43018-020-0028-410.1038/s43018-020-0028-4 ↗
37. 10.1016/j.chembiol.2020.07.00710.1016/j.chembiol.2020.07.007 ↗
38. 10.1126/sciadv.abb522310.1126/sciadv.abb5223 ↗
39. 10.1021/acsnano.1c0436310.1021/acsnano.1c04363 ↗
40. 10.1038/ni.193710.1038/ni.1937 ↗
41. 10.1073/pnas.060195610310.1073/pnas.0601956103 ↗
42. 10.1126/sciadv.aay160110.1126/sciadv.aay1601 ↗
43. 10.1016/j.tips.2017.11.00310.1016/j.tips.2017.11.003 ↗
44. 10.1039/C8CS00641E10.1039/C8CS00641E ↗
45. 10.1016/S1470-2045(19)30326-210.1016/S1470-2045(19)30326-2 ↗
46. 10.1016/j.ijrobp.2021.06.04110.1016/j.ijrobp.2021.06.041 ↗
47. 10.1002/adma.20180224410.1002/adma.201802244 ↗
48. 10.1142/S179354581642003710.1142/S1793545816420037 ↗
49. 10.1186/s12951-020-00678-310.1186/s12951-020-00678-3 ↗
50. 10.1038/s41565-020-0759-510.1038/s41565-020-0759-5 ↗
51. 10.1038/s41563-020-0755-z10.1038/s41563-020-0755-z ↗
52. 10.1021/acscentsci.1c0077910.1021/acscentsci.1c00779 ↗
53. 10.1016/j.addr.2008.03.01610.1016/j.addr.2008.03.016 ↗
54. 10.1038/nmat220210.1038/nmat2202 ↗
55. 10.1002/adma.20120044610.1002/adma.201200446 ↗
56. 10.1038/s41467-020-16339-w10.1038/s41467-020-16339-w ↗
57. 10.1038/s41467-019-12857-410.1038/s41467-019-12857-4 ↗